insights_auto
„Outlook“: 95.0 proc. tikisi, kad kaina augs·0.0 proc. tikisi, kad kaina kris
Eiti į analizęchevron_right
LILY34:BVMF
Eli Lilly and Company
271,25 BRL
arrow_downward
−1,83%(−5,06) 1 D.
11-17, 17:54:41 GMT−3 · BRL
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „LILY34“ įžvalgos...
Atidaryti
271,90 BRL
Aukšta
276,36 BRL
Žema
269,80 BRL
Rinkos kapitalizacija
1,33 trln.
Vid. kiekis
52,07 tūkst.
Apimtis
24,69 tūkst.
52 sav. aukšta
281,50 BRL
52 sav. žema
141,59 BRL
Neapmokėtos akcijos
940,75 mln.
Darbuotojų skaičius
50 tūkst.
Atidaryti
271,90 BRL
Aukšta
276,36 BRL
Žema
269,80 BRL
Rinkos kapitalizacija
1,33 trln.
Vid. kiekis
52,07 tūkst.
Apimtis
24,69 tūkst.
52 sav. aukšta
281,50 BRL
52 sav. žema
141,59 BRL
Neapmokėtos akcijos
940,75 mln.
Darbuotojų skaičius
50 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
The Business Journals
·
prieš 2 valandas
Lilly signs $5.9B cancer research deal with Cambridge company
Seeking Alpha
·
prieš 3 valandas
Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Investing.com
·
prieš 7 valandas
RBC Capital reiterates Eli Lilly stock rating on pipeline focus
BioSpace
·
prieš 7 valandas
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
Profilis
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Apie „Eli Lilly and Company“
Generalinis direktoriusDavid A. Ricks
Darbuotojai50 tūkst.
Įkurta1876
Pagrindinė būstinėIndianapolis, Indiana, Jungtinės Valstijos
SektoriusHealth Care
Pramonės sritis-
Svetainėlilly.com